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expression and/or high expression levels of complement defense molecules (Teeling et al, 2004 ). In addition, the binding of ofatumumab induces cell death through antibody-dependent cell-mediated cytotoxicity (Teeling et al, 2006) .
In follicular and mantle cell lymphoma, serum rituximab concentrations have been correlated with clinical response in some studies (Berinstein et al, 1998 ; Igarashi et al, 2002;
Plosker et al, 2003; Tobinai et al, 2004) , although 2 other studies showed no such correlation (Tobinai et al, 1998; Mangel et al, 2003) . Alemtuzumab, a monoclonal antibody that targets the CD52 antigen, has been characterized with respect to its pharmacokinetics and exposureresponse relationship in CLL patients. Alemtuzumab displayed time-and concentration- dependent pharmacokinetics with large interpatient variability (Mould et al, 2007) . A relationship between maximal trough concentrations and clinical outcome was observed, and increasing alemtuzumab exposure resulted in a greater probability of tumor inhibition. 9 Recently, Daydé et al. showed in a murine model of human CD20 + lymphoma that rituximab exposure was inversely correlated with tumor burden and influenced response and survival (Daydé et al,2009 ). These observations are in accordance with a study of ofatumumab in a mouse xenograft model (Bleeker et al, 2008) .
The pharmacokinetic profile of ofatumumab has been described in patients with relapsed or refractory follicular lymphoma (Hagenbeek et al, 2008) . Overall, the AUC increased with dose in a superproportionate manner, but no association between pharmacokinetics and response was found in this phase 1-2 trial.
Here we present the PK profile of ofatumumab in patients with relapsed or refractory CLL and show by non-compartmental and compartmental analyses that pharmacokinetic/pharmacodynamic (PK/PD) associations indeed exist. Such relationships may prove useful for optimizing doses and schedules of CD20 antibodies in CLL and other B−cell malignancies. The main exclusion criteria were significant acute or chronic co-morbidity; treatment with rituximab, alemtuzumab, or autologous stem cell transplantation within the last 6 months; and previous treatment with allogeneic stem cell transplantation. A detailed description of the patients has been published (Coiffier et al, 2008) see Table I .
The trial was performed in accordance with Good Clinical Practices and local regulatory requirements. The trial protocol was approved by the appropriate national authorities and institutional review boards/ethics committees (see affiliations list). Each patient gave written informed consent in accordance with the Declaration of Helsinki to participate.
Trial design
This open-label phase 1-2 trial was performed between September 2004 and April 2006. The primary objective, which has been published (Coiffier et al, 2008) , was to evaluate the safety and efficacy of ofatumumab in patients with CLL. The secondary objective, and the focus of the present work, was to determine the pharmacokinetics after a single dose and after 4 weekly doses of ofatumumab in patients with CLL.
Patients received 4 weekly infusions of ofatumumab at 3 different dose levels. The 3 patients in cohort A received a first infusion of 100 mg ofatumumab and 3 subsequent infusions of 500 mg. The 3 patients of cohort B received a first infusion of 300 mg and 3 subsequent infusions of 1000 mg and the 27 patients of cohort C received a first infusion of 500 mg and 3 subsequent infusions of 2000 mg. Enrollment in cohorts B and C was initiated when the 3 patients in the previous cohort had received all 4 infusions and had satisfactory safety evaluations after 1 week follow up (see Coiffier et al, 2008) , for a detailed description of the pre-medication given in connection with the ofatumumab infusions). During the treatment phase, the patients were followed for safety assessments, and samples for efficacy measurements (flow cytometry analyses) and pharmacokinetics were obtained. Levels of circulating B cells were assessed via the surrogate marker CD19 and via CD20 (BARC, Ghent, Belgium). No infection prophylaxis was scheduled in the protocol.
Pharmacokinetic assessments
Pharmacokinetic samples were taken on days 0 (before, during, and after infusion), 1, 3, 5, 7, 14, 21 (before, during, and after infusion), 25, week 4, week 7, week 27, month 9, and month 12. The concentration of ofatumumab was determined in serum using a sandwich immunoassay (Hagenbeek et al, 2008) .
Serum samples were collected to determine the pharmacokinetics both after a single dose and after 4 weekly doses of ofatumumab. Thus the non-compartmental PK parameters were derived from the PK samples taken immediately before the first infusion up until the second infusion, and from the PK samples taken immediately before the fourth infusion and thereafter (software used: WinNonLin version 5.01).
The parameters were: area under concentration-time curve extrapolated to infinity (AUC 0-∞ ), maximum and minimum concentrations of ofatumumab (C max , C trough ), time of C max 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Toxicity
The analysis of the relationship between toxicity and PK parameters focused on the occurrence of infections, and incidences of toxicity were defined as adverse events coded as belonging to the 'infections and infestations' system organ class in the Medical Dictionary for Regulatory Activities (MedDRA, version 6.0). One incidence of infectious interstitial lung disease was not included in the correlation analysis because the adverse event was classified in the system organ class 'respiratory, thoracic and mediastinal disorders'. For a complete analysis of ofatumumab safety, see Coiffier et al, 2008 .
Non-compartmental statistical analyses
Analysis and presentation of non-compartmental PK parameters were made for patients with robust parameter estimates (i.e., patients for whom the linear regression model of the elimination phase had an adequate fit (R 2 >0.9). Two-sided non-parametric tests (Wilcoxon) The relationships between time-to-event endpoints (PFS, duration of response, time to next anti-CLL therapy) and log-transformed PK parameters (AUC 0-∞ , C max , C trough , T ½ , and CL after the fourth infusion) were investigated using Cox regression. In these analyses, time−to−event endpoints were censored at the time of the last relevant assessment.
Hazard ratio >1 is associated with increased risk and <1 with decreased risk.
Compartmental pharmacokinetic modeling
The ofatumumab concentration-time profiles from cohort C were fitted by a first-order, linear two−compartment model as illustrated in Figure 1 (software used: SAS version 9.2) (Kuester et al, 2006) . The i.v. infusion rate was assumed to be constant over the dosing interval, τ, at 21 . The elimination rate constant was denoted k 10 and was allowed to differ between the first infusion and the remaining infusion visits, with the change in rate given by δ 10 .
The full population data were fitted by a non-linear mixed effect model, where k 21 was included as a fixed effect and k 12 , k 10 , δ 10 , and V1 were included as random effects and assumed to be mutually independent and log-normally distributed. A number of concentration measurements were recorded below the limit of quantification and were included in the analysis as censored observations. The residual errors were assumed to be mutually independent and normally distributed with mean zero and variance σ 2 . For model evaluation, the residuals were plotted against the predicted values. One extreme observation was omitted from the plot, to keep the axis symmetric.
Compartmental statistical analysis
For cohort C the possible association between the estimated PK parameters and demographic characteristics and baseline information was investigated by ANOVA. The log−transformed PK parameters, k 10 , k 12 , δ 10 , and V1, were analyzed separately, including a covariate in each analysis. The covariates considered were gender, age, height, body weight, BMI, time since CLL diagnosis, Binet stage, modified Rai stage, SPD at screening, and B-cell count at baseline (measured by flow cytometry). The effect of PK parameters on clinical response was investigated by logistic regression, where also baseline SPD and body weight were included as covariates. 
Results

Patients
Thirty-three patients took part in the trial. Three patients were allocated to each of cohorts A and B and 27 were allocated to cohort C. All patients completed treatment except one patient in cohort C who was withdrawn after the first infusion.
A detailed description of the demographics and baseline characteristics for all patients is outlined in Table I . In cohort C, the numbers of males/females were 12/15, the median age of the patients was 63 years (range 27 to 82 years), the median body weight was 70.0 kg, 
Pharmacokinetic evaluation
All patients attained measurable concentrations of ofatumumab after the first infusion, and serum concentrations increased during the subsequent treatment course. Serum concentrations were measurable up to 4 weeks after the last infusion in the lower dose cohorts (cohorts A and B) and up to approximately 7 months in a small number of patients in the highest dose cohort (cohort C; Figure 2 ).
A summary of non-compartmental PK parameters after the first and fourth infusion of ofatumumab is presented in Table II . Values for AUC 0-∞ and C max tended to increase more than proportionally with dose. T ½ appeared constant across the lower dose cohorts, with longer T ½ in the higher dose cohort. After the first infusion, CL tended to decrease with dose, whereas after the fourth infusion, the CL was relatively constant across dose cohorts. As can be seen from Table II , the values for AUC 0-∞ and CL showed considerable variability among patients in cohort C. The variation could partly be explained by differences in baseline characteristics between the patients, as gender and SPD at screening were found to be significant predictors of systemic exposure (AUC) and clearance (Cl). At the first infusion baseline SPD was predictive for AUC and clearance (p<0.05). At the fourth infusion both gender and SPD were predictive for AUC and clearance (p<0.05). None of the other covariates (age, height, body weight, BMI, time since CLL diagnosis, Binet stage, modified
Rai stage, and B-cell count at baseline) considered were found to be statistical significant predictors of exposure measured by AUC and Cl.
Relationship of non-compartmental pharmacokinetic parameters to clinical response, time-to-event endpoints and infection variables.
The primary efficacy variable, objective response over the period from screening to week 19, is presented in Table III .
The relation between clinical response, exposure to ofatumumab (measured by AUC and Cl) and SPD at screening are illustrated in Figure 3 . For example Figure 3A shows AUC versus baseline SPD for responders and non-responders. A clear, vertical separation is seen between responders and non responders, indicating that high systemic exposure is associated with a higher likelihood of being responder, but there also seems to be an increasing trend with SPD at screening, indicating that high SPD at screening is associated with high systemic exposure after forth infusion. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 for AUC). Similarly, responding patients had higher C trough and longer T ½ than patients without a response (p=0.008 and p=0.001, respectively) (data not shown). Conversely, the CL was lower in responding patients than in non-responders (p<0.001; Figure 3B and 3D). The association between these PK parameters and the objective response was still found to be (Table IV) . Kaplan-Meier estimates for time-to-event endpoints for patients with Figure 5A '-5D'. The relation between time-to-event endpoints and clearance, now evaluated by a log-rank test, was highly significant for time to progression and time to next therapy (p<0.0001 figure 5A' and p<0.007 figure 5D').
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Compartmental model evaluation and qualification
The compartment model was evaluated graphically. The plots of the first six patients included in cohort C with individual observed and predicted PK profiles are presented in Figure 6A .
The circles represent observed concentrations, the dots represent observations below lower level of quantification (LLOQ), and the full line represents the predicted profile (by empirical Bayes prediction). The predicted random effects were plotted in Quantile-Quantile (QQ)-plots to evaluate the normality assumption. A QQ-plot of log(k 10 ) is shown in Figure 6B . If the assumptions are fulfilled, the predicted random effects should form a straight line.
Quantile−Quantile-plots of log(k 12 ), log(δ 10 ), and log(V1) showed similar patterns (data not shown). Finally, a residual plot for all observations is presented in Figure 6C . One extreme observation was omitted from the plot to keep the axis symmetric.
The graphical model evaluation showed good fit of the individual predictions to the observed profiles. Similarly, the assumption of normality of the random effects and the 
Relationship of compartmental PK parameters to patient covariates and objective response
The statistically significant associations between baseline characteristics and compartmental model-based PK parameters are shown in Table V . The analyses showed that male patients had faster elimination compared to female patients and that high SPD at baseline was associated with faster elimination, after both first and fourth infusion. The gender, body weight and BMI of the patients were associated with the estimated volume of distribution, since male patients were seen to have larger volume of distribution compared to female patients and high and B-cell count at baseline had no statistically significant association with the model-based PK parameters.
The compartmental analyses also showed statistically significant associations between estimated elimination rate constants after first and fourth infusion and objective response (Table VI) . The finding that fast elimination predicts a lower probability of objective response was also valid when adjusted for body weight and baseline SPD. The estimated volume of distribution was seen to be significantly associated with objective response, since larger volume of distribution predicts lower probability of objective response. There was no indication of an effect of distribution rate constants on objective response. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The tumor burden in mice receiving the same dose of rituximab influenced the efficacy, and rituximab exposure subsequently affected both response and survival. These observations are in accordance with a study of ofatumumab in a mouse xenograft model where tumor load had a major impact on ofatumumab plasma concentrations (Bleeker et al, 2008) ..However, in CLL patients, the tumor burden can only be measured indirectly by surrogate parameters, such as SPD and lymphocyte counts, and the tumor load in organs such as bone marrow, liver, and spleen can not be quantified.
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In the compartmental analysis, a high AUC, high C max , and a low CL is reflected in a slow elimination rate constant. In the present work, the compartmental PK analyses showed that SPD, a surrogate for tumor burden, was a significant predictor for the elimination rate constant. High SPD at baseline was associated with faster elimination both at the first and fourth infusion. In turn, the elimination rate constant was a significant predictor for clinical Binet stages were not related to the elimination rate constant.
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Tables and figures
Ofatumumab serum concentrations during trial in cohort A (A), cohort B (B), and cohort C (C).
Pharmacokinetic samples were taken on days 0 (before, during, and after infusion), 1, 3, 5, 7, 14, 21 (before, during, and after infusion), 25, week 4, week 7, week 27, month 9, and month 12.
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